Quinapril Chemical Properties

Melting point:

120-130°C

Boiling point:

662.0±55.0 °C(Predicted)

Density 

1.217±0.06 g/cm3(Predicted)

pka

3.39±0.20(Predicted)

BCS Class

1

CAS DataBase Reference

85441-61-8(CAS DataBase Reference)

Safety Information

Safety Statements 

22-24/25

Quinapril Usage And Synthesis

Description

Quinapril is an orally active, non-sulfhydryl ACE inhibitor reportedly useful in the treatment of essential hypertension. The main claimed advantage of quinapril compared with other available ACE inhibitors is its side-effect profile. It is also effective in the management of congestive heart failure.

Originator

Warner-Lambert (USA)

Uses

Antihypertensive; enzyme inhibitor (angiotensin-converting).

Definition

ChEBI: Quinapril is a member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug and an antihypertensive agent. It is a member of isoquinolines, a dicarboxylic acid monoester, an ethyl ester and a tertiary carboxamide.

brand name

Accupril (Pfizer); Quinapril (Lupin); Quinapril (Ranbaxy) ;Accupro.

Clinical Use

Angiotensin converting enzyme inhibitor:
Hypertension
Congestive heart failure

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia, hypotension and renal failure with ARBs and aliskiren.
Bee venom extract: possible severe anaphylactoid reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Cytotoxics: increased risk of angioedema with everolimus.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Gold: flushing and hypotension with sodium aurothiomalate.
Lithium: reduced excretion (possibility of enhanced lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Metabolism

Quniapril is a prodrug which is metabolised in the liver to its active form, quinaprilat, and to minor inactive metabolites.
Quinaprilat is eliminated primarily by renal excretion.

Quinapril(85441-61-8)Related Product Information

• Propyl butyrate
• 5,6,7,8-TETRAHYDROISOQUINOLINE
• Propyl gallate
• Phenylhydrazine
• Isoquinoline
• PHENYL VALERATE
• Quinapril benzyl ester maleate
• Carbonyl iron powder
• Quinapril hydrochloride
• Isoquinoline-1-carboxylic acid
• N-[S-(2-PYRIDYLTHIO)CYSTEAMINYL]ETHYLENEDIAMINE-N,N,N',N'-TETRAACETIC ACID, MONOAMIDE
• QUINAPRIL RELATED COMPOUND A ETHYL[3S-[2(R*),3A,11A BETA]]-1,3,4,6,11,11A-HEXAHYDRO-3-METHYL-1,4-DIOXO-ALPHA-(2-PHENYLETHYL)-2H-PYRAZINO[1,2-B]ISOQUINOLINE-2-ACETATE USP
• QUINAPRILAT
• Quinapril